A phase II study of Pembrolizumab plus Carboplatin in BRCA-related metastatic breast cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515686-34-00

Acronym

PEMBRACA

Enrollment

Registered

2024-11-12

Start date

2018-11-16

Completion date

Unknown

Last updated

2025-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRCA-related metastatic breast cancer

Brief summary

The objective response rate

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGPEMBROLIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The objective response rate	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026